HIVDB 9.5.1 (2023-11-05) Drug resistance interpretation: PR

PI Major Mutations:

None

PI Accessory Mutations:

None

PR Other Mutations:

113V 99% - K20R 94% - E35D 94% - M36I 97% - N37D 94% - R41K 88% - K45R 94% - R57K 98% - L63P 94% - H69K 82% - K70R 88% - L89M 98% 600/934,913 - 600/934,913

Protease Inhibitors

Susceptible atazanavir/r (ATV/r) darunavir/r (DRV/r) Susceptible fosamprenavir/r (FPV/r) Susceptible indinavir/r (IDV/r) Susceptible Susceptible lopinavir/r (LPV/r) nelfinavir (NFV) Susceptible saquinavir/r (SQV/r) Susceptible tipranavir/r (TPV/r) Susceptible

PR comments

Other

K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for Pl.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: NNRTI Mutations: K70KE E: 61%, K: 30% - M184V 97% court 13151

K103N 97% P225H 91% con-6,269

RT Other Mutations:

K20R 70% - V35T 90% - K43KR R 70% K 20% - V60I 90% - V60I 90% - V60I 90% - V245E 80% - V24

1293V 97% P294T 94% E312D 94%

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC) Intermediate Resistance zidovudine (AZT) Susceptible stavudine (D4T) Low-Level Resistance Low-Level Resistance didanosine (DDI) emtricitabine (FTC) High-Level Resistance High-Level Resistance lamivudine (3TC) Low-Level Resistance tenofovir (TDF)

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR) Intermediate Resistance efavirenz (EFV) High-Level Resistance etravirine (ETR) Susceptible High-Level Resistance nevirapine (NVP)

rilpivirine (RPV)

RT comments

NRTI

- K70/E/Q/N/T/S/G cause low-leve resistance to ABC and TDF.
- M184V/I cause high-level in vitro resistance to ATC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility).
 M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.

Susceptible

NNRTI

- K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
- P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.

Drug	resistance	ı
		-

Rule

K70KE

M184V

K70KE + M184V


Total

mutation scores of NRTI:

-10











Download CSV

TDF 0

15

HIVDB 9.5.1 (2023-11-05)













-10











15

30

Rule	DOR \$	EFV \$	ETR \$	NVP \$	RPV
K103N + P225H	10	0	0	0	0
P225H	20	45	0	45	0
K103N	0	60	0	60	0
Total	30	105	0	105	0